Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis

doi:10.3748/wjg.v30.i4.318

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 4

This Article

(136)

(155)

(0)

(13)

(4935)

(12)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jan 28, 2024; 30(4): 318-331
Published online Jan 28, 2024. doi: 10.3748/wjg.v30.i4.318

Table 3 Summary of adverse events, n (%)

	Before PSM				After PSM
	Triple therapy group (n = 324)		AIPB group (n = 118)		Triple therapy group (n = 88)		AIPB group (n = 88)
	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4	Grade 1-2	Grade 3-4
Fever	67 (20.7)	23 (7.1)	4 (3.4)	2 (1.7)	20 (22.7)	8 (9.1)	4 (4.5)	0 (0)
Nausea	100 (30.9)	0 (0)	6 (5.1)	0 (0)	24 (27.3)	0 (0)	5 (5.7)	0 (0)
Vomit	32 (9.9)	15 (4.6)	7 (5.9)	6 (5.1)	7 (8.0)	3 (3.4)	6 (6.8)	4 (4.5)
Abdominal pain	97 (29.9)	162 (50.0)	18 (15.3)	18 (15.3)	24 (27.3)	44 (50.0)	15 (17.0)	13 (14.8)
ALT increased	79 (24.4)	125 (38.6)	32 (27.1)	39 (33.1)	27 (30.4)	33 (37.5)	22 (25.0)	29 (33.0)
AST increased	130 (40.1)	161 (49.7)	36 (30.5)	44 (37.3)	40 (45.5)	49 (55.7)	26 (29.5)	34 (38.6)
Hyperbilirubinemia	37 (11.4)	7 (2.2)	7 (5.9)	11 (9.3)	10 (11.4)	0 (0)	4 (4.5)	8 (9.1)
Anemia	37 (11.4)	8 (2.5)	7 (5.9)	4 (3.4)	11 (12.5)	1 (1.1)	5 (5.7)	3 (3.4)
Neutropenia	86 (26.5)	20 (6.2)	9 (7.6)	12 (10.2)	29 (33.0)	5 (5.7)	5 (5.7)	9 (10.2)
Thrombocytopenia	103 (31.8)	90 (27.8)	27 (22.9)	20 (16.9)	24 (27.3)	16 (18.2)	20 (22.7)	13 (14.8)
Bleeding	48 (14.8)	3 (0.9)	1 (0.8)	1 (0.8)	12 (13.6)	1 (1.1)	1 (1.1)	1 (1.1)
Diarrhea	62 (19.1)	60 (18.5)	22 (18.6)	3 (2.5)	17 (19.3)	5 (5.7)	17 (19.3)	3 (3.4)
Hoarseness	80 (24.7)	0 (0)	13 (11.0)	0 (0)	21 (23.9)	0 (0)	10 (11.4)	0 (0)
Rash	92 (28.4)	4 (1.2)	28 (23.7)	4 (3.4)	24 (27.3)	0 (0)	20 (22.7)	3 (3.4)
HFS	69 (21.3)	9 (2.8)	19 (16.1)	18 (15.3)	18 (20.5)	1 (1.1)	14 (15.9)	11 (12.5)
Hypertension	76 (23.5)	11 (3.4)	31 (26.3)	34 (28.8)	22 (25.0)	3 (3.4)	23 (26.1)	27 (30.7)
RCCEP	42 (13.0)	14 (4.3)	16 (13.6)	6 (5.1)	11 (12.5)	5 (5.7)	13 (14.8)	6 (6.8)
Hypothyroidism	64 (19.8)	8 (2.5)	2 (1.7)	0 (0)	18 (20.5)	2 (2.3)	0 (0)	0 (0)
Fatigue	32 (9.9)	31 (9.6)	4 (3.4)	4 (3.4)	6 (6.8)	8 (9.1)	3 (3.4)	2 (2.3)
Hepatitis	10 (3.1)	1 (0.3)	0 (0)	0 (0)	5 (5.7)	1 (1.1)	0 (0)	0 (0)
Coma	0 (0)	2 (0.6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

AFP: Alpha-fetoprotein; AIPB: Angiogenesis inhibitors and programmed cell death protein 1/programmed cell death ligand 1 blockers; triple therapy: Hepatic arterial infusion chemotherapy plus angiogenesis inhibitors and programmed cell death protein 1/programmed cell death ligand 1 blockers; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HFS: Hand-foot syndrome; RCCEP: Reactive cutaneous capillary endothelial proliferation.

Full Size Table

Citation: Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis. World J Gastroenterol 2024; 30(4): 318-331
URL: https://www.wjgnet.com/1007-9327/full/v30/i4/318.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i4.318

Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis. World J Gastroenterol 2024; 30(4): 318-331 [PMID: 38313229 DOI: 10.3748/wjg.v30.i4.318]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.